TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A 12-Month, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Reslizumab (3.0 mg/kg) in the Reduction of Clinical Asthma Exacerbations in Patients (12-75 Years of Age) With Eosinophilic Asthma
Brief Summary: The primary objective of this study is to determine whether reslizumab is more effective than placebo in reducing the number of clinical asthma exacerbations (CAEs) in patients with eosinophilic asthma.


Options:
A: Arm Label: Mepolizumab; Type: EXPERIMENTAL; Interventions: Drug: Mepolizumab, Drug: OCS (prednisone/prednisolone) | Arm Label: Placebo; Type: EXPERIMENTAL; Interventions: Drug: Placebo, Drug: OCS (prednisone/prednisolone) | Intervention Type: DRUG; Name: Mepolizumab; Assigned to Arm(s): Mepolizumab | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: OCS (prednisone/prednisolone); Assigned to Arm(s): Mepolizumab, Placebo
B: Arm Label: Mepolizumab 750mg; Type: ACTIVE_COMPARATOR; Interventions: Biological: Mepolizumab 750 | Arm Label: Mepolizumab 250mg; Type: ACTIVE_COMPARATOR; Interventions: Biological: Mepolizumab 250 | Arm Label: Mepolizumab 75mg; Type: ACTIVE_COMPARATOR; Interventions: Biological: Mepolizumab 75 | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo saline | Intervention Type: BIOLOGICAL; Name: Mepolizumab 750; Assigned to Arm(s): Mepolizumab 750mg | Intervention Type: BIOLOGICAL; Name: Mepolizumab 250; Assigned to Arm(s): Mepolizumab 250mg | Intervention Type: BIOLOGICAL; Name: Mepolizumab 75; Assigned to Arm(s): Mepolizumab 75mg | Intervention Type: DRUG; Name: Placebo saline; Assigned to Arm(s): Placebo
C: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Reslizumab 3.0 mg/kg; Type: EXPERIMENTAL; Interventions: Drug: Reslizumab | Intervention Type: DRUG; Name: Reslizumab; Assigned to Arm(s): Reslizumab 3.0 mg/kg | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: CNTO 148 (golimumab); Type: EXPERIMENTAL; Interventions: Drug: CNTO148 | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: CNTO148; Assigned to Arm(s): CNTO 148 (golimumab) | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Assessment of the Efficacy and Tolerability of Two Formulations of Atorvastatin In Korean Adult With Hypercholesterolemia : A Multicenter, Prospective, Open-Label, Randomized, Trial
Brief Summary: There will be no significant differences in the efficacy and tolerability between the test and reference formulations of atorvastatin 20 mg in these Korean adults with primary hypercholesterolemia.


Options:
A: Arm Label: Lipinon-test formulation of atrovastain - 20mg; Type: EXPERIMENTAL; Interventions: Drug: Atorvastatin (Lipinon) | Arm Label: Lipitor- branded formuation of atorvastatin-20mg; Type: ACTIVE_COMPARATOR; Interventions: Drug: Atorvastatin (Lipitor) | Intervention Type: DRUG; Name: Atorvastatin (Lipinon); Assigned to Arm(s): Lipinon-test formulation of atrovastain - 20mg | Intervention Type: DRUG; Name: Atorvastatin (Lipitor); Assigned to Arm(s): Lipitor- branded formuation of atorvastatin-20mg
B: Intervention Type: DRUG; Name: Atorvastatin; Assigned to Arm(s): N/A
C: Arm Label: simvastatin/ezetimibe (vytorin) group; Type: EXPERIMENTAL; Interventions: Drug: simvastatin/ezetimibe | Arm Label: atorvastatin group; Type: ACTIVE_COMPARATOR; Interventions: Drug: atorvastatin 20mg | Intervention Type: DRUG; Name: simvastatin/ezetimibe; Assigned to Arm(s): simvastatin/ezetimibe (vytorin) group | Intervention Type: DRUG; Name: atorvastatin 20mg; Assigned to Arm(s): atorvastatin group
D: Arm Label: atorvastatin 10 mg, 80 mg; Type: EXPERIMENTAL; Interventions: Drug: statin | Intervention Type: DRUG; Name: statin; Assigned to Arm(s): atorvastatin 10 mg, 80 mg

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: An Open-Label, Multicenter, Randomized, Phase 3 Study of S-1 and Cisplatin Compared With 5-FU and Cisplatin in Patients With Metastatic Diffuse Gastric Cancer Previously Untreated With Chemotherapy
Brief Summary: The purpose of this study is to evaluate the safety and efficacy of S-1 and Cisplatin compared to 5-FU and Cisplatin in treatment of patients with metastatic diffuse gastric and gastro-esophageal junction cancer previously untreated with chemotherapy.


Options:
A: Intervention Type: DRUG; Name: continuous infusion of 5-fluorouracil; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: combination of irinotecan and cisplatin; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: oral administration of S-1; Assigned to Arm(s): N/A
B: Arm Label: Standard taxane therapy; Type: ACTIVE_COMPARATOR; Interventions: Drug: Taxane | Arm Label: trastuzumab emtansine 2.4 mg; Type: EXPERIMENTAL; Interventions: Drug: trastuzumab emtansine | Arm Label: trastuzumab emtansine 3.6 mg; Type: EXPERIMENTAL; Interventions: Drug: trastuzumab emtansine | Intervention Type: DRUG; Name: Taxane; Assigned to Arm(s): Standard taxane therapy | Intervention Type: DRUG; Name: trastuzumab emtansine; Assigned to Arm(s): trastuzumab emtansine 3.6 mg | Intervention Type: DRUG; Name: trastuzumab emtansine; Assigned to Arm(s): trastuzumab emtansine 2.4 mg
C: Arm Label: S-1+Cisplatin; Type: EXPERIMENTAL; Interventions: Drug: S-1 (Tegafur+Gimeracil+Oteracil) /cisplatin (investigational arm) | Arm Label: 5FU+Cisplatin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Fluorouracil/cisplatin (control arm) | Intervention Type: DRUG; Name: S-1 (Tegafur+Gimeracil+Oteracil) /cisplatin (investigational arm); Assigned to Arm(s): S-1+Cisplatin | Intervention Type: DRUG; Name: Fluorouracil/cisplatin (control arm); Assigned to Arm(s): 5FU+Cisplatin
D: Arm Label: Arm A, - Modified DCF; Type: ACTIVE_COMPARATOR; Interventions: Drug: Docetaxel, Leucovorin, Fluorouracil, Cisplatin | Arm Label: ARM B - Parent DCF with G-CSF; Type: ACTIVE_COMPARATOR; Interventions: Drug: Docetaxel, Cisplatin, Fluorouracil, Neulasta, or Neupogen | Arm Label: Arm C - Modifid DCF + Trastuzumab; Type: ACTIVE_COMPARATOR; Interventions: Drug: Docetaxel, Leukvorin, Flurouracil, Cisplatin, Trastuzumab | Intervention Type: DRUG; Name: Docetaxel, Leucovorin, Fluorouracil, Cisplatin; Assigned to Arm(s): Arm A, - Modified DCF | Intervention Type: DRUG; Name: Docetaxel, Cisplatin, Fluorouracil, Neulasta, or Neupogen; Assigned to Arm(s): ARM B - Parent DCF with G-CSF | Intervention Type: DRUG; Name: Docetaxel, Leukvorin, Flurouracil, Cisplatin, Trastuzumab; Assigned to Arm(s): Arm C - Modifid DCF + Trastuzumab

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Primary Prevention of Allergic Disease in Early Child by Lactobacillus Reuteri
Brief Summary: An altered microbial exposure may be partly responsible for the increase of allergic diseases in populations with a western lifestyle. Activation of the immune system by microbes early in life is probably required for an accurate maturation of the immune system. Probiotics, live bacteria which are considered to confer health when ingested, have been suggested to prevent eczema and sensitisation infants.

The aim of this study is to assess the effect of oral supplementation with the probiotic bacterium Lactobacillus reuteri in infancy on the development of allergic disease and sensitisation during the first 2 years of life and to examine mechanisms possibly underlying eventual effects on allergic manifestations.

A follow up was performed at 7 years of age.


Options:
A: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: Placebo | Arm Label: Lactobacillus reuteri; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Lactobacillus reuteri | Intervention Type: DIETARY_SUPPLEMENT; Name: Lactobacillus reuteri; Assigned to Arm(s): Lactobacillus reuteri | Intervention Type: DIETARY_SUPPLEMENT; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: probiotics & allergy; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Lactobacillus rhamnosus GG | Intervention Type: DIETARY_SUPPLEMENT; Name: Lactobacillus rhamnosus GG; Assigned to Arm(s): probiotics & allergy
C: Arm Label: LP GMNL-133 group; Type: EXPERIMENTAL; Interventions: Biological: LP GMNL-133 capsule | Arm Label: LF GM-090 group; Type: EXPERIMENTAL; Interventions: Biological: LF GM-090 capsule | Arm Label: LP GMNL-133+LF GM-090 group; Type: EXPERIMENTAL; Interventions: Biological: LP GMNL-133 +LF GM-090 capsule | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Biological: Placebo | Intervention Type: BIOLOGICAL; Name: LP GMNL-133 capsule; Assigned to Arm(s): LP GMNL-133 group | Intervention Type: BIOLOGICAL; Name: LF GM-090 capsule; Assigned to Arm(s): LF GM-090 group | Intervention Type: BIOLOGICAL; Name: LP GMNL-133 +LF GM-090 capsule; Assigned to Arm(s): LP GMNL-133+LF GM-090 group | Intervention Type: BIOLOGICAL; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: Infants drink formula added with LGG; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Casein hydrolysate added with LGG | Arm Label: Infants drink casein hydrolysate without LGG; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: Infants drink casein hydrolysate without LGG | Intervention Type: DIETARY_SUPPLEMENT; Name: Casein hydrolysate added with LGG; Assigned to Arm(s): Infants drink formula added with LGG | Intervention Type: DIETARY_SUPPLEMENT; Name: Infants drink casein hydrolysate without LGG; Assigned to Arm(s): Infants drink casein hydrolysate without LGG

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Tailored Communication to Reduce Cardiovascular Risk
Brief Summary: The primary goal of the trial is to test the feasibility and efficacy of a cardiovascular disease quality improvement system that couples EMR-based patient identification with individually tailored patient messages. The study will test the hypothesis that that a tailored patient-directed approach to cardiovascular risk reduction integrated into patients' primary care delivery site will improve control of elevated low-density lipoprotein cholesterol and other card iac risk factors more than routine care alone for patients at intermediate or high risk for cardiovascular disease.


Options:
A: Arm Label: WHO CVD Risk Assessment package; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: WHO CVD risk assessment package | Arm Label: Health Insurance only; Type: SHAM_COMPARATOR; Interventions: Behavioral: Health Insurance only | Intervention Type: BEHAVIORAL; Name: WHO CVD risk assessment package; Assigned to Arm(s): WHO CVD Risk Assessment package | Intervention Type: BEHAVIORAL; Name: Health Insurance only; Assigned to Arm(s): Health Insurance only
B: Arm Label: Direct-to-patient tailored cardiovascular risk message system; Type: EXPERIMENTAL; Interventions: Behavioral: Direct-to-patient tailored cardiovascular risk message system | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Direct-to-patient tailored cardiovascular risk message system; Assigned to Arm(s): Direct-to-patient tailored cardiovascular risk message system
C: Arm Label: Care coordinator + Decision Support Software; Type: EXPERIMENTAL; Interventions: Other: Care Coordinator + Decision Support Software | Arm Label: Usual care; Type: ACTIVE_COMPARATOR; Interventions: Other: Usual care | Intervention Type: OTHER; Name: Care Coordinator + Decision Support Software; Assigned to Arm(s): Care coordinator + Decision Support Software | Intervention Type: OTHER; Name: Usual care; Assigned to Arm(s): Usual care
D: Intervention Type: DEVICE; Name: Decision Aid Statin Choice; Assigned to Arm(s): N/A

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: FL3X: An Adaptive Intervention to Improve Outcomes for Youth With Type 1 Diabetes
Brief Summary: The purpose of this study is to see if a behavioral intervention for adolescents with type 1 diabetes will improve adherence to T1D self-management activities and improve diabetes outcomes. We expect the intervention to improve diabetes outcomes when compared to usual care.


Options:
A: Arm Label: SLCBT; Type: EXPERIMENTAL; Interventions: Behavioral: Cognitive Behavioral Therapy & Social Learning | Arm Label: SLCBT-R; Type: EXPERIMENTAL; Interventions: Behavioral: Cognitive Behavioral Therapy & Social Learning | Arm Label: ES; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Education and Support | Intervention Type: BEHAVIORAL; Name: Cognitive Behavioral Therapy & Social Learning; Assigned to Arm(s): SLCBT, SLCBT-R | Intervention Type: BEHAVIORAL; Name: Education and Support; Assigned to Arm(s): ES
B: Arm Label: Coaching group for lifestyle changes; Type: EXPERIMENTAL; Interventions: Behavioral: Coaching | Arm Label: Routine pediatric care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Coaching; Assigned to Arm(s): Coaching group for lifestyle changes
C: Arm Label: CAPS; Type: EXPERIMENTAL; Interventions: Behavioral: Counselor-assisted problem solving (CAPS) | Arm Label: IRC; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Internet-resource comparison (IRC) | Intervention Type: BEHAVIORAL; Name: Counselor-assisted problem solving (CAPS); Assigned to Arm(s): CAPS | Intervention Type: BEHAVIORAL; Name: Internet-resource comparison (IRC); Assigned to Arm(s): IRC
D: Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: FL3X: Flexible Lifestyle Empowering Change | Intervention Type: BEHAVIORAL; Name: FL3X: Flexible Lifestyle Empowering Change; Assigned to Arm(s): Intervention

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Group Cognitive Processing Therapy for Combat-related PTSD
Brief Summary: The purpose of this study is to compare group-administered Cognitive Processing Therapy-Cognitive-only version (CPT-C), an evidence based treatment for posttraumatic stress disorder (PTSD), to Present Centered Therapy (PCT) in order to determine whether the results of CPT exceed those of receiving a therapy that focuses on current problems rather than past trauma in a group format.


Options:
A: Arm Label: Minimal Contact Control; Type: OTHER; Interventions: Behavioral: Minimal Contact Control | Arm Label: PE-Massed; Type: EXPERIMENTAL; Interventions: Behavioral: Prolonged Exposure Therapy - Massed | Arm Label: PE-Spaced; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Prolonged Exposure Therapy - Spaced | Arm Label: Present-Centered Therapy (PCT); Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Present-Centered Therapy | Intervention Type: BEHAVIORAL; Name: Prolonged Exposure Therapy - Massed; Assigned to Arm(s): PE-Massed | Intervention Type: BEHAVIORAL; Name: Prolonged Exposure Therapy - Spaced; Assigned to Arm(s): PE-Spaced | Intervention Type: BEHAVIORAL; Name: Minimal Contact Control; Assigned to Arm(s): Minimal Contact Control | Intervention Type: BEHAVIORAL; Name: Present-Centered Therapy; Assigned to Arm(s): Present-Centered Therapy (PCT)
B: Arm Label: Group Cognitive Processing Therapy-Cognitive Only; Type: EXPERIMENTAL; Interventions: Behavioral: Group Cognitive Processing Therapy-Cognitive Only | Arm Label: Group Present Centered Therapy; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Group Present Centered Therapy | Intervention Type: BEHAVIORAL; Name: Group Cognitive Processing Therapy-Cognitive Only; Assigned to Arm(s): Group Cognitive Processing Therapy-Cognitive Only | Intervention Type: BEHAVIORAL; Name: Group Present Centered Therapy; Assigned to Arm(s): Group Present Centered Therapy
C: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Prolonged Exposure | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Present Centered Therapy | Intervention Type: PROCEDURE; Name: Prolonged Exposure; Assigned to Arm(s): 1 | Intervention Type: PROCEDURE; Name: Present Centered Therapy; Assigned to Arm(s): 2
D: Arm Label: Arm 1: Mindfulness-Based Stress Reduction (MBSR); Type: EXPERIMENTAL; Interventions: Behavioral: Mindfulness-Based Stress Reduction (MBSR) | Arm Label: Arm 2: Present-Centered Group Therapy (PCGT); Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Present-Centered Group Therapy (PCGT) | Intervention Type: BEHAVIORAL; Name: Mindfulness-Based Stress Reduction (MBSR); Assigned to Arm(s): Arm 1: Mindfulness-Based Stress Reduction (MBSR) | Intervention Type: BEHAVIORAL; Name: Present-Centered Group Therapy (PCGT); Assigned to Arm(s): Arm 2: Present-Centered Group Therapy (PCGT)

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Evaluation of Novel Transition Interventions for Youth With Congenital Heart Disease
Brief Summary: The objective of this study is to evaluate the potential role of a cardiology clinic-based educational intervention for 15 to 17 year olds with congenital heart disease (CHD) and their parents, and to determine whether this intervention results in improved self-management skills (e.g., renewing medication prescriptions), teens having greater knowledge of their heart condition, and more teen and parent satisfaction with services. The results of this study will form the basis for a website that in turn may serve as an additional means of providing transition interventions. The results of this study may also be applicable to youth with other special health care needs.


Options:
A: Intervention Type: BEHAVIORAL; Name: Screening (Behavior); Assigned to Arm(s): N/A
B: Arm Label: SMS and Internet; Type: EXPERIMENTAL; Interventions: Behavioral: MD2ME | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: MD2ME; Assigned to Arm(s): SMS and Internet
C: Arm Label: Clinic-based Educational Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Clinic-based Educational Intervention | Arm Label: Usual Care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Clinic-based Educational Intervention; Assigned to Arm(s): Clinic-based Educational Intervention
D: Arm Label: Intrinsic Motivation; Type: EXPERIMENTAL; Interventions: Behavioral: MI + CATCH-IT Internet Site | Arm Label: Extrinsic Motivation; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: BA (brief advice) + CATCH-IT Internet site | Intervention Type: BEHAVIORAL; Name: MI + CATCH-IT Internet Site; Assigned to Arm(s): Intrinsic Motivation | Intervention Type: BEHAVIORAL; Name: BA (brief advice) + CATCH-IT Internet site; Assigned to Arm(s): Extrinsic Motivation

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A 12-Month, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Reslizumab (3.0 mg/kg) in the Reduction of Clinical Asthma Exacerbations in Patients (12-75 Years of Age) With Eosinophilic Asthma
Brief Summary: This is a Phase 3, multicenter, randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy, safety, and immunogenicity of treatment with reslizumab in patients with eosinophilic asthma.


Options:
A: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Reslizumab 3.0 mg/kg; Type: EXPERIMENTAL; Interventions: Drug: Reslizumab | Intervention Type: DRUG; Name: Reslizumab; Assigned to Arm(s): Reslizumab 3.0 mg/kg | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Active; Type: ACTIVE_COMPARATOR; Interventions: Drug: GSK679586 | Intervention Type: DRUG; Name: GSK679586; Assigned to Arm(s): Active | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: Mepolizumab; Type: EXPERIMENTAL; Interventions: Drug: Mepolizumab | Intervention Type: DRUG; Name: Mepolizumab; Assigned to Arm(s): Mepolizumab
D: Arm Label: Eosinophilic phenotype (EOS+) Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Arm Label: EOS+ Benralizumab (2 mg); Type: EXPERIMENTAL; Interventions: Biological: Benralizumab 2 mg | Arm Label: EOS+ Benralizumab (20 mg); Type: EXPERIMENTAL; Interventions: Biological: Benralizumab 20 mg | Arm Label: EOS+ Benralizumab (100 mg); Type: EXPERIMENTAL; Interventions: Biological: Benralizumab 100 mg | Arm Label: Non-eosinophil phenotype (EOS-) Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Arm Label: EOS- Benralizumab (100 mg); Type: EXPERIMENTAL; Interventions: Biological: Benralizumab 100 mg | Intervention Type: BIOLOGICAL; Name: Benralizumab 2 mg; Assigned to Arm(s): EOS+ Benralizumab (2 mg) | Intervention Type: BIOLOGICAL; Name: Benralizumab 20 mg; Assigned to Arm(s): EOS+ Benralizumab (20 mg) | Intervention Type: BIOLOGICAL; Name: Benralizumab 100 mg; Assigned to Arm(s): EOS+ Benralizumab (100 mg), EOS- Benralizumab (100 mg) | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Eosinophilic phenotype (EOS+) Placebo, Non-eosinophil phenotype (EOS-) Placebo

Answer: A